| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Research Abstract |
In normal condition, lipid accumulation is not observed in the kidney. In progressive kidney diseases, however, lipid is commonly accumulated in tubular epithelial cells of the kidney. We previously showed that LXR agonist, a drug known to activate lipid metabolism in the liver, reduced accumulated lipid in diseased kidney, and also urinary protein level in an animal model. In the present study, we have proposed that the induction of apolipoprotein M in the kidney by the drug is a part of its therapeutic effect for the kidney disease.
|
